A-Z Clinical Trials Unit

阿拉巴马州到赞比亚临床试验单位(A-to-Z CTU)代表着华盛顿大学和赞比亚大学之间的合作 阿拉巴马州伯明翰(UAB)和赞比亚传染病研究中心(CIDRZ)。UAB有 自1990年以来一直得到资助，用于进行由NIH资助的艾滋病毒网络临床试验，并在2015年补充说 CIDRZ CRS应DAIDS的要求。在过去的6年里，我们的团队成功地招募了1000多人 参与者，包括45%的女性和59%的少数民族参与者，参加了48个网络试验，并为 该网络的175种出版物。我们已经达到或超过了在招生、保留、 数据管理、药房管理以及实验室设施和指标。该公司过去的表现 A-to-Z CTU证明了我们的团队准备为NIH资助的HIV临床的科学做出贡献 在接下来的七年里试验网络。在此应用程序中，我们强调了从A到Z的CTU对艾滋病毒的承诺 研究的具体目标如下： 目标1.在我们的两个临床研究地点有效地招募和留住参与者参加艾滋病毒临床试验 产生最高质量的数据，以满足HVTN、HPTN和ACTG科学研究的需要 网络及其各自的科学研究议程。 目标2.保持一个由调查人员和工作人员组成的具有凝聚力的综合团队，在这种情况下，沟通、社区 参与、互动、解决问题、灵活的人员配置、质量数据和样本管理，以及 通过我们高质量业绩的记录，目前存在明显的监管保证。 目标3.通过与网络领导层保持接触，为各自的科学议程做出贡献 对新出现的科学优先事项做出快速反应，包括快速扩大方案的能力- 为任何由DAIDS资助的研究网络提供有针对性的、高优先级研究的特定站点。 目标4.指导一群才华横溢的年轻调查人员，他们将为在 这一不断变化的国内和国际艾滋病毒研究领域。 我们将利用我们在临床试验方面的长期经验，通过美国国立卫生研究院为艾滋病毒研究做出贡献- 资助艾滋病毒临床试验网络。

The Alabama to Zambia Clinical Trials Unit (A-to-Z CTU) represents a collaboration between the University of Alabama at Birmingham (UAB) and the Centre for Infectious Diseases Research in Zambia (CIDRZ). UAB has been continuously funded to perform NIH-funded HIV network clinical trials since 1990 and in 2015 added the CIDRZ CRS at the request of DAIDS. Over the past 6 years, our team has successfully enrolled over 1000 participants, including 45% female and 59% minority participants, into 48 network trials and contributed to over 175 publications of the networks. We have met or exceeded the expectations regarding enrollment, retention, data management, pharmacy management, and laboratory facilities and metrics. The past performance of the A-to-Z CTU exemplifies the preparedness of our team to contribute to the science of the NIH-funded HIV clinical trials networks for the next seven years. In this application, we highlight the A-to-Z CTU commitment to HIV research with the following specific aims: Aim 1. Enroll and retain participants efficiently into HIV clinical trials at our two clinical research sites capable of yielding the highest quality data to meet the needs of the HVTN, the HPTN and the ACTG scientific networks and their respective scientific research agendas. Aim 2. Maintain a cohesive, integrated group of investigators and staff where communication, community engagement, interaction, problem solving, flexible staffing, quality data and sample management, and regulatory assurance currently exist as evident via our track record of high-quality performance. Aim 3. Contribute to the respective scientific agendas by remaining engaged with the network leadership to respond quickly to emerging scientific priorities, including the ability to rapidly scale-up a protocol- specific site for targeted, high-priority studies for any DAIDS-funded research network. Aim 4. Mentor a talented group of young investigators who will lay the foundation for continued excellence in this ever-changing field of HIV research domestically and internationally. We will leverage our long-standing experience in clinical trials to contribute to HIV research through the NIH- funded HIV clinical trial networks.